Hi Kiska. The advancement of ADC drugs like Enhertu in breast cancers is making it difficult for immutep to progress in this cancer indication. Not much data for adc outside breast cancer. Efti still very much kicking goals in lung and head/neck. Efti might also be combined with adc’s just like we exploring combo with keytruda.Future looking good for immutep.
Media, page-477
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.010(3.57%) |
Mkt cap ! $421.8M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.0¢ | 27.5¢ | $814.3K | 2.871M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 186340 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 136417 | 6 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |